Gilead Sciences, Inc. (GILD) revenue by segment
GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 12/30102% above fair value
$168.98−1.28 (-0.75%)
Close on Nov 18, 2026Market cap $209.59BP/E –Yield 1.87%
Doanh thu theo bộ phận của Gilead Sciences, Inc.
Theo bộ phận kinh doanh
Theo sản phẩm hoặc dịch vụ
| Doanh thu | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % doanh thu | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product sales | $28.92B | $28.61B | $26.93B | $26.98B | $27.01B | $24.36B | $22.12B | $21.68B | $25.66B | $29.95B | 98.2% | +1.1% |
| Total HIV | $20.75B | $19.61B | $18.18B | $17.19B | $16.32B | $16.94B | $16.44B | $14.63B | – | – | 70.5% | +5.8% |
| Biktarvy | $14.33B | $13.42B | $11.85B | $10.39B | $8.62B | $7.26B | $4.74B | $1.18B | $0 | $0 | 48.7% | +6.8% |
| Total Oncology | $3.24B | $3.29B | $2.93B | $2.14B | $1.25B | – | – | – | – | – | 11.0% | -1.6% |
| Total Liver Disease | $3.22B | $3.02B | $2.78B | $2.80B | $2.85B | – | – | – | – | – | 10.9% | +6.5% |
| Descovy | $2.76B | $2.11B | $1.99B | $1.87B | $1.70B | $1.86B | $1.50B | $1.58B | $1.22B | $298.00M | 9.4% | +30.5% |
| Total Cell Therapy | $1.84B | $1.97B | $1.87B | $1.46B | $871.00M | $607.00M | $456.00M | $264.00M | – | – | 6.2% | -6.8% |
| Genvoya | $1.50B | $1.76B | $2.06B | $2.40B | $2.88B | $3.34B | $3.93B | $4.62B | $3.67B | $1.48B | 5.1% | -15.0% |
| Yescarta | $1.50B | $1.57B | $1.50B | $1.16B | $695.00M | $563.00M | $456.00M | $264.00M | $7.00M | $0 | 5.1% | -4.8% |
| Intangible asset Trodelvy | $1.40B | $1.32B | $1.06B | $680.00M | $380.00M | $49.00M | $0 | – | – | – | 4.7% | +6.2% |
| Sofosbuvir/Velpatasvir | $1.27B | $1.60B | $1.54B | $1.53B | $1.46B | $1.60B | $1.97B | $1.97B | $3.51B | – | 4.3% | -20.3% |
| Odefsey | $1.17B | $1.29B | $1.35B | $1.47B | $1.57B | $1.67B | $1.66B | $1.60B | $1.11B | $329.00M | 4.0% | -9.4% |
| Vemlidy | $1.07B | $959.00M | $862.00M | $842.00M | $814.00M | $657.00M | $488.00M | – | – | – | 3.6% | +11.6% |
| Veklury | $911.00M | $1.80B | $2.18B | $3.91B | $5.57B | $2.81B | $0 | $0 | – | – | 3.1% | -49.4% |
| Other Liver Disease | $874.00M | $467.00M | $385.00M | $426.00M | – | – | – | – | – | – | 3.0% | +87.2% |
| Total Other | $799.00M | $889.00M | $859.00M | $946.00M | $1.03B | $1.03B | $1.55B | $3.10B | – | – | 2.7% | -10.1% |
| Royalty, contract and other revenues | $527.00M | $144.00M | $182.00M | $299.00M | $297.00M | $334.00M | $330.00M | $450.00M | $445.00M | $437.00M | 1.8% | +266.0% |
| AmBisome | $509.00M | $533.00M | $492.00M | $497.00M | $540.00M | $436.00M | $407.00M | $420.00M | $366.00M | $356.00M | 1.7% | -4.5% |
| Other HIV | $500.00M | $434.00M | $401.00M | $530.00M | $195.00M | $407.00M | $47.00M | $61.00M | $58.00M | $47.00M | 1.7% | +15.2% |
| Symtuza - Revenue share | $495.00M | $592.00M | $529.00M | $530.00M | – | – | – | – | – | – | 1.7% | -16.4% |
| Tecartus | $344.00M | $403.00M | $370.00M | $299.00M | $176.00M | $44.00M | $0 | $0 | – | – | 1.2% | -14.6% |
| Other | $290.00M | $356.00M | $367.00M | $449.00M | $281.00M | $276.00M | $203.00M | $218.00M | $1.18B | $4.21B | 1.0% | -18.5% |
| Letairis | – | – | $142.00M | $196.00M | $206.00M | $314.00M | $618.00M | $943.00M | $887.00M | $819.00M | – | – |
| Revenue share - Symtuza | – | – | $529.00M | $530.00M | $531.00M | $488.00M | $379.00M | $79.00M | $0 | $0 | – | – |
| Complera/Eviplera | – | – | $129.00M | $200.00M | $258.00M | $269.00M | $406.00M | $653.00M | $966.00M | $1.46B | – | – |
| Stribild | – | – | $101.00M | $127.00M | $189.00M | $196.00M | $369.00M | $644.00M | $1.05B | $1.91B | – | – |
| Truvada | – | – | $114.00M | $147.00M | $371.00M | $1.45B | $2.81B | $3.00B | $3.13B | $3.57B | – | – |
| Ledipasvir/Sofosbuvir | – | – | $70.00M | $115.00M | $212.00M | $272.00M | $643.00M | $1.22B | $4.37B | – | – | – |
| Other HCV | – | – | $160.00M | $166.00M | $207.00M | $193.00M | $328.00M | $498.00M | – | – | – | – |
| Total HCV | – | – | $1.77B | $1.81B | $1.88B | $2.06B | $2.94B | $3.69B | – | – | – | – |
| Other HB/HDV | – | – | $72.00M | $55.00M | $44.00M | $18.00M | $11.00M | – | – | – | – | – |
| Total HBV/HDV | – | – | $1.02B | $988.00M | $969.00M | $860.00M | $742.00M | – | – | – | – | – |
| Viread | – | – | $83.00M | $91.00M | $111.00M | $185.00M | $243.00M | – | $1.05B | $1.19B | – | – |
| Ranexa | – | – | – | – | $10.00M | $9.00M | $216.00M | $758.00M | $717.00M | $677.00M | – | – |
| Zydelig | – | – | – | – | $62.00M | $72.00M | $103.00M | $133.00M | $149.00M | $168.00M | – | – |
| Atripla | – | – | – | – | $145.00M | $349.00M | $600.00M | $1.21B | $1.81B | $2.61B | – | – |
| Other Products, Vemlidy | – | – | – | – | – | $657.00M | $488.00M | $321.00M | $122.00M | $3.00M | – | – |
| Other Products, Viread | – | – | – | – | – | $185.00M | $243.00M | $307.00M | $1.05B | $1.19B | – | – |
| Trodelvy | – | – | – | – | – | $49.00M | $0 | $0 | – | – | – | – |
| Vosevi | – | – | – | – | – | – | $257.00M | $396.00M | $293.00M | $0 | – | – |
| Epclusa | – | – | – | – | – | – | – | $1.97B | $3.51B | $1.75B | – | – |
| Harvoni | – | – | – | – | – | – | – | $1.22B | $4.37B | $9.08B | – | – |
| Intangible Asset - Ranexa | – | – | – | – | – | – | – | – | $717.00M | $677.00M | – | – |
| Other Products | – | – | – | – | – | – | – | – | $207.00M | $188.00M | – | – |
| Antiviral Products | – | – | – | – | – | – | – | – | $23.34B | $27.75B | – | – |
| Sovaldi | – | – | – | – | – | – | – | – | $964.00M | $4.00B | – | – |
| Other antiviral products | – | – | – | – | – | – | – | – | $196.00M | $72.00M | – | – |
Theo khu vực
| Doanh thu | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % doanh thu | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $20.88B | $20.59B | $19.44B | $18.88B | $19.27B | $18.22B | $16.65B | $16.27B | $18.19B | $19.35B | 70.9% | +1.4% |
| Europe | $5.06B | $4.63B | $4.31B | $4.47B | $4.87B | $4.14B | $3.81B | $4.01B | $5.31B | $6.37B | 17.2% | +9.3% |
| Rest of World | $3.50B | $3.53B | $3.37B | $3.93B | $3.16B | $2.34B | $1.99B | $1.85B | $2.60B | $4.67B | 11.9% | -0.7% |
| Other Countries | – | – | – | – | – | – | – | – | $2.60B | $4.67B | – | – |
| Japan | – | – | – | – | – | – | – | – | – | $2.53B | – | – |
Lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K, 10-Q của Gilead Sciences (XBRL). Số quý 4 bằng cả năm tài chính trừ chín tháng đầu. Tên bộ phận giữ theo cách công ty tự đặt và có thể đổi khi công ty tái cấu trúc. Tab KPI hiện các bộ phận này cạnh chỉ số vận hành của Gilead Sciences, kèm đầy đủ lịch sử, biểu đồ và liên kết tới từng hồ sơ.
Chỉ số vận hành
| Countries of operation | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | YoY |
|---|---|---|---|---|---|---|
| Countries of operation | 35 | 35 | 35 | 35 | 35 | 0.0% |
Các số lượng và quy mô Gilead Sciences gắn thẻ trong thuyết minh hồ sơ 10-K, 10-Q (XBRL), tính đến cuối mỗi kỳ. Phần phân tách giữ theo cách công ty tự đặt tên; mỗi chỉ số hiện tối đa 15 dòng.
See a number that looks wrong?